Publications by authors named "S Cicchelli"
Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach.
Int J Dermatol
December 2022
Article Synopsis
- Long-term management of psoriasis is crucial but challenging; the PSO-LONG trial showed that a combination treatment of betamethasone dipropionate and calcipotriol foam, applied twice a week for a year, can reduce relapses but still needs further investigation for long-term use.
- In the ProActive Management (PAM) program, experts reached consensus on 14 out of 18 statements, recognizing the importance of proactive topical treatments to minimize relapse risk, especially for resistant disease sites or when other therapies are not suitable.
- Establishing proactive strategies in treatment guidelines is seen as vital for improving the management of mild to moderate psoriasis, while more research on patient adherence is necessary.
Background: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis in up to one third of psoriatic patients. Clinically it's characterized from an insidious onset. To help clinicians screen for PsA, several screening tools have been developed.
View Article and Find Full Text PDFPrimary cutaneous B-cell lymphoma: narrative review of the literature.
G Ital Dermatol Venereol
August 2019
Primary cutaneous B-cell lymphomas comprehend a group of lymphoproliferative disorders characterized by being monoclonal proliferations of B-cell primarily involving the skin. Despite being recognized as autonomous and distinct clinico-pathologic entities since the late 80s, their classification is still an ongoing matter of debate. At the moment, WHO classification recognizes three disorders: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma and primary cutaneous diffuse large b-cell lymphoma (leg type).
View Article and Find Full Text PDFThe term "Primary Cutaneous B-Cell Lymphoma" (PCBCL) comprehends a variety of lymphoproliferative disorders characterized by a clonal proliferation of B-cells primarily involving the skin. The absence of evident extra-cutaneous disease must be confirmed after six-month follow-up in order to exclude a nodal non-Hodgkin's lymphoma (NHL) with secondary cutaneous involvement, which may have a completely different clinical behavior and prognosis. In this article, we have summarized the clinico-pathological features of main types of PCBCL and we outline the guidelines for management based on a review of the available literature.
View Article and Find Full Text PDFBackground: Psoriasis is sustained by pro-inflammatory CD4+ T helper cells mainly belonging to the Th1, Th17 and Th22 lineage.
Objective: To identify whether treatment with the anti-tumour-necrosis-factor antagonist etanercept is able to induce significant modulations in transcription factor and cytokine mRNA gene expressions related to the different T cell immune response polarization (Th1, Th2, Th17 and regulatory T cells, Treg and to correlate them with clinical response.
Methods: The study population included 19 psoriasis patients treated with etanercept and 19 healthy subjects.